NO965083L - Uracilderivater og anti-tumoreffekt-potentiator og antitumormiddel inneholdende dem - Google Patents
Uracilderivater og anti-tumoreffekt-potentiator og antitumormiddel inneholdende demInfo
- Publication number
- NO965083L NO965083L NO965083A NO965083A NO965083L NO 965083 L NO965083 L NO 965083L NO 965083 A NO965083 A NO 965083A NO 965083 A NO965083 A NO 965083A NO 965083 L NO965083 L NO 965083L
- Authority
- NO
- Norway
- Prior art keywords
- group
- lower alkyl
- substituted
- hydrogen atom
- alkyl group
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 7
- -1 methanesulfonyloxy, amino Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 abstract 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Organic Insulating Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7166795 | 1995-03-29 | ||
| PCT/JP1996/000828 WO1996030346A1 (en) | 1995-03-29 | 1996-03-28 | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965083D0 NO965083D0 (no) | 1996-11-28 |
| NO965083L true NO965083L (no) | 1997-01-27 |
| NO308033B1 NO308033B1 (no) | 2000-07-10 |
Family
ID=13467185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO965083A NO308033B1 (no) | 1995-03-29 | 1996-11-28 | Uracilderivater, anvendelse derav, antitumoreffektpotentiator og antitumormiddel inneholdende dem samt farmasøytiske preparater |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US5744475A (no) |
| EP (1) | EP0763529B1 (no) |
| JP (1) | JP3088757B2 (no) |
| KR (1) | KR100424934B1 (no) |
| AT (1) | ATE245631T1 (no) |
| AU (1) | AU681321B2 (no) |
| CA (1) | CA2191340C (no) |
| DE (1) | DE69629156T2 (no) |
| DK (1) | DK0763529T3 (no) |
| ES (1) | ES2203683T3 (no) |
| HU (1) | HU227726B1 (no) |
| NO (1) | NO308033B1 (no) |
| PT (1) | PT763529E (no) |
| WO (1) | WO1996030346A1 (no) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227726B1 (en) * | 1995-03-29 | 2012-01-30 | Taiho Pharmaceutical Co Ltd | Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same |
| JP3088758B2 (ja) | 1996-09-24 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体を含有する癌転移抑制剤 |
| US6235782B1 (en) | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| US6235776B1 (en) | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| AU5526400A (en) * | 1999-05-31 | 2000-12-18 | Ernst Burgisser | Thymine derivatives that possess antiviral and antitumoral effects |
| JP4110347B2 (ja) * | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| ES2363766T3 (es) * | 2002-08-21 | 2011-08-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibidores de nucleosidasas y fosforilasas de nucleosidos. |
| EP1673353A4 (en) * | 2003-09-05 | 2007-03-28 | Einstein Coll Med | TRANSITION STATE AND INHIBITORS OF THYMIDINE PHOSPHORY LASE |
| US7622580B2 (en) * | 2004-08-13 | 2009-11-24 | Xerox Corporation | Colorant compounds |
| US7211131B2 (en) * | 2004-08-13 | 2007-05-01 | Xerox Corporation | Phase change inks |
| RU2394581C2 (ru) * | 2005-01-26 | 2010-07-20 | Тайхо Фармасьютикал Ко., Лтд. | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| ES2382673T3 (es) | 2006-04-13 | 2012-06-12 | Taiho Pharmaceutical Co., Ltd. | Agente terapéutico para la enfermedad inflamatoria intestinal |
| BRPI0713333A2 (pt) * | 2006-06-30 | 2012-03-06 | Taiho Pharmaceutical Co., Ltd. | Potencializador de terapia de radiação |
| EP2211956A4 (en) | 2007-10-10 | 2014-07-09 | Parion Sciences Inc | DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA |
| TWI435725B (zh) * | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
| TWI429439B (zh) * | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
| PT2295414E (pt) * | 2008-06-03 | 2012-11-30 | Taiho Pharmaceutical Co Ltd | Composto de uracilo que possui actividade inibidora sobre a desoxiuridina-trifosfatase humana ou um seu sal |
| CA2729191A1 (en) * | 2008-07-01 | 2010-01-07 | Gifu University | Novel imino derivatives, methods for producing the same and insecticides containing the same |
| JP2010202591A (ja) * | 2009-03-04 | 2010-09-16 | Hokkaido Univ | 増殖性疾患の内用放射線治療剤 |
| JP6219271B2 (ja) | 2011-06-07 | 2017-10-25 | パリオン・サイエンシィズ・インコーポレーテッド | 治療の方法 |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI615145B (zh) | 2013-03-27 | 2018-02-21 | Taiho Pharmaceutical Co Ltd | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 |
| US9616081B2 (en) | 2013-03-27 | 2017-04-11 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
| NZ714014A (en) | 2013-05-17 | 2017-06-30 | Taiho Pharmaceutical Co Ltd | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| BR112015031619B1 (pt) | 2013-06-17 | 2023-01-17 | Taiho Pharmaceutical Co., Ltd | Formas cristalinas i e iii de cloridrato de 5-cloro-6-(2-iminopirrolidin-1-il)metil-2,4(1h,3h)-pirimidinodiona, composição farmacêutica e método de produção |
| WO2015034032A1 (ja) | 2013-09-06 | 2015-03-12 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN106333952A (zh) * | 2014-02-19 | 2017-01-18 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945384B (zh) * | 2014-03-25 | 2018-10-16 | 江苏豪森药业集团有限公司 | 5-氯-6-[(2-亚氨基-1-吡咯烷)甲基]-2,4(1h,3h)-嘧啶二酮或其盐的制备方法 |
| CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| JP6458007B2 (ja) | 2014-04-04 | 2019-01-23 | 大鵬薬品工業株式会社 | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| CN106317028A (zh) * | 2015-11-03 | 2017-01-11 | 江苏悦兴药业有限公司 | 抗肿瘤药物盐酸替比拉西的制备方法及其关键中间体 |
| CN105906573A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种替吡嘧啶中间体的制备方法 |
| MA43590A (fr) | 2016-01-08 | 2018-11-14 | Taiho Pharmaceutical Co Ltd | Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral |
| TWI791430B (zh) | 2016-02-05 | 2023-02-11 | 日商大鵬藥品工業股份有限公司 | 針對具有重度腎功能障礙之癌症患者之治療方法 |
| WO2018129514A1 (en) | 2017-01-09 | 2018-07-12 | Shuttle Pharmaceuticals, Llc | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
| CN106831607A (zh) * | 2017-02-14 | 2017-06-13 | 山东创新药物研发有限公司 | 一种6‑氯甲基尿嘧啶的合成方法 |
| CN106892902A (zh) * | 2017-03-01 | 2017-06-27 | 国药心制药有限公司 | 一种盐酸替匹嘧啶及其中间体6‑氯甲基尿嘧啶的合成方法 |
| JP7168575B2 (ja) | 2017-03-17 | 2022-11-09 | レ ラボラトワール セルヴィエ | トリフルリジン／チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 |
| WO2019002407A1 (en) | 2017-06-28 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | PROCESS FOR THE PREPARATION OF TIPIRACIL CHLORHYDRATE |
| WO2019049174A1 (en) * | 2017-09-07 | 2019-03-14 | Msn Laboratories Private Limited, R&D Center | SOLID STATE FORMS OF 5-CHLORO-6 - [(2-IMINOPYRROLIDIN-1-YL) METHYL] PYRIMIDINE-2,4- (1H, 3H) -DIONE HYDROCHLORIDE AND METHODS OF PREPARATION THEREOF |
| JP7330180B2 (ja) * | 2017-11-02 | 2023-08-21 | プロコス ソシエタ ペル アチオニ | チピラシル塩酸塩結晶ｉｉｉ型の製造方法 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US11730753B2 (en) | 2018-03-03 | 2023-08-22 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
| US11465988B2 (en) | 2018-12-15 | 2022-10-11 | Natco Pharma Limited | Process for the preparation of Tipiracil hydrochloride and intermediates thereof |
| CN109796441B (zh) * | 2019-02-19 | 2020-10-16 | 北京民康百草医药科技有限公司 | 一种盐酸替比嘧啶的杂质a的制备方法 |
| CN114057697B (zh) * | 2020-08-07 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种替吡嘧啶中间体的制备方法 |
| AR127893A1 (es) | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820712A (en) * | 1986-08-27 | 1989-04-11 | Stichting Katholieke Universiteit | Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds |
| KR0155168B1 (ko) * | 1989-09-29 | 1998-11-16 | 미우라 아끼라 | 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제 |
| JPH0751567B2 (ja) * | 1989-09-29 | 1995-06-05 | 三菱化学株式会社 | ６―置換アシクロピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤 |
| JPH075465B2 (ja) * | 1990-03-29 | 1995-01-25 | 三菱化学株式会社 | 抗ウイルス剤 |
| DE69126469T2 (de) * | 1990-03-29 | 1998-01-29 | Mitsubishi Chem Corp | Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten |
| HU227726B1 (en) * | 1995-03-29 | 2012-01-30 | Taiho Pharmaceutical Co Ltd | Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same |
-
1996
- 1996-03-28 HU HU9603280A patent/HU227726B1/hu unknown
- 1996-03-28 JP JP08529175A patent/JP3088757B2/ja not_active Expired - Lifetime
- 1996-03-28 AU AU51216/96A patent/AU681321B2/en not_active Expired
- 1996-03-28 AT AT96907693T patent/ATE245631T1/de active
- 1996-03-28 DE DE69629156T patent/DE69629156T2/de not_active Expired - Lifetime
- 1996-03-28 DK DK96907693T patent/DK0763529T3/da active
- 1996-03-28 KR KR1019960706628A patent/KR100424934B1/ko not_active Expired - Lifetime
- 1996-03-28 US US08/737,677 patent/US5744475A/en not_active Expired - Lifetime
- 1996-03-28 CA CA002191340A patent/CA2191340C/en not_active Expired - Lifetime
- 1996-03-28 ES ES96907693T patent/ES2203683T3/es not_active Expired - Lifetime
- 1996-03-28 PT PT96907693T patent/PT763529E/pt unknown
- 1996-03-28 EP EP96907693A patent/EP0763529B1/en not_active Expired - Lifetime
- 1996-03-28 WO PCT/JP1996/000828 patent/WO1996030346A1/ja not_active Ceased
- 1996-11-28 NO NO965083A patent/NO308033B1/no not_active IP Right Cessation
-
1998
- 1998-01-12 US US09/006,009 patent/US6159969A/en not_active Expired - Lifetime
-
1999
- 1999-12-09 US US09/457,668 patent/US6294535B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2203683T3 (es) | 2004-04-16 |
| NO308033B1 (no) | 2000-07-10 |
| US6159969A (en) | 2000-12-12 |
| EP0763529B1 (en) | 2003-07-23 |
| DE69629156T2 (de) | 2004-05-06 |
| DE69629156D1 (de) | 2003-08-28 |
| WO1996030346A1 (en) | 1996-10-03 |
| KR970703326A (ko) | 1997-07-03 |
| EP0763529A4 (en) | 1998-07-08 |
| HU227726B1 (en) | 2012-01-30 |
| KR100424934B1 (ko) | 2004-07-27 |
| EP0763529A1 (en) | 1997-03-19 |
| CA2191340A1 (en) | 1996-10-03 |
| JP3088757B2 (ja) | 2000-09-18 |
| DK0763529T3 (da) | 2003-11-10 |
| AU681321B2 (en) | 1997-08-21 |
| AU5121696A (en) | 1996-10-16 |
| US5744475A (en) | 1998-04-28 |
| CA2191340C (en) | 2001-04-17 |
| HUP9603280A3 (en) | 2001-04-28 |
| HUP9603280A2 (hu) | 1998-01-28 |
| ATE245631T1 (de) | 2003-08-15 |
| NO965083D0 (no) | 1996-11-28 |
| PT763529E (pt) | 2003-12-31 |
| US6294535B1 (en) | 2001-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO965083D0 (no) | Uracilderivater og anti-tumoreffekt-potentiator og antitumormiddel inneholdende dem | |
| GEP20094627B (en) | High drug load tablet | |
| DK0784054T3 (da) | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister | |
| TR200003598T2 (tr) | Amid türevleri ve nosiseptin antagonistleri | |
| DE69118082D1 (de) | Imidazolderivate, starke und selektive Angiotensin-II-Rezeptor-Antagonisten | |
| IL146309A0 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
| HUT61735A (en) | Heterocyclic group-substituted guanidine derivatives, process for their production and insecticidal compositions comprising same | |
| ATE94534T1 (de) | Antiarrhythmische verbindungen. | |
| EP1344525A4 (en) | ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM | |
| DK0591528T3 (da) | Pyrazolo[1,5-a]pyrimidinderivat og antiinflammatorisk middel, der indeholder dette | |
| PT628311E (pt) | Derivado de xantina com actividade antidepressiva | |
| ATE79380T1 (de) | 2-substituierte-e-kondensierte(1,2,4>triazolo(1,5-c>pyrimidine, pharmazeutische zubereitungen und ihre verwendung. | |
| ATE101181T1 (de) | Anti-krebs-verbindungen. | |
| HUT62582A (en) | Process for producing pyrimidine nucleoside derivatives and pharmaceutical compositions comprising same as active ingredient | |
| EP0852499A4 (en) | THERAPEUTIC AZID COMPOUNDS | |
| PT884051E (pt) | Inibidores de metasteses cancerosas contendo derivados de uracilo | |
| ATE134646T1 (de) | C63-amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplanine | |
| MX9300423A (es) | Derivados heterociclicos. | |
| HU9300202D0 (en) | Benzo-pyrane derivatives, pharmaceutical preparatives containing them as active substance as well as method for producing them | |
| DE69426620D1 (de) | Antidepressiva | |
| EP0379737A3 (en) | Dihydropyridine derivatives for the treatment of angiospasm | |
| GB9124002D0 (en) | Benzimidazole anthelmintic agents | |
| YU38498A (sh) | Derivati 2-(arilfenil)amino-imidazolina | |
| TH36111A (th) | อนุพันธ์ไพแรโซล | |
| NO940360L (no) | Heterocykliske derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |